<img alt="" src="https://secure.52enterprisingdetails.com/787780.png" style="display:none;">
Skip to content

Pharmacovigilance services

Pharmacovigilance, or drug safety, is crucial to understanding a drug, biologic or combination product’s risk-benefit profile and protecting the welfare of patients by systematically detecting and assessing adverse events. 

Pharmacovigilance servicestwo-women-notes

We offer pharmacovigilance services including SUSAR reporting, medical monitoring, and coding of adverse events, medical history and prior/concomitant medications.

Monitoring drug safety

Pharmacovigilance is the study of detecting, assessing, and understanding adverse effects to monitor the safety of medicines. Drug safety monitoring is performed during clinical studies and we can support you with medical monitoring, SAE reporting, and SUSAR reporting to the regulatory authorities. In addition, pharmacovigilance is an important part of the product’s entire lifecycle and we also support sponsors with routine safety reporting to the authorities (DSURs/PSURs).

Medical monitors work closely with the sponsor and sites to perform qualified medical reviews of, for example, SAEs/SUSARs as well as providing general oversight and immediate support when safety issues arise. We understand that when it comes to safety, what we do is as important as how we do it, and in addition to regulatory compliance, we believe that clear communication, efficient reporting procedures, and seamless collaboration are essential for success.

Pharmacovigilance services also include:

  • Safety reporting including SUSARs, DSURs/PSURs, and patient safety narratives
  • Medical monitoring including medical review of clinical data and consultation with medical monitors
  • Coding of adverse events, medical history and prior/concomitant medications

Contact us for more information

Ulrika Heldestad
Ulrika Heldestad
BD & Sales Director

Leave a contact request

Latest news

Notice about a change in some of our email addresses

As part of the upcoming company split on 1 January 2026, some of our email domains will change to @labquality.com...

How do you shape regulatory complexity into strategic clarity?

As AI continues to reshape healthcare, clear guidance on health data use is more critical than ever. Building on the...

Fast track for mononational clinical trial applications in Sweden

Starting September 1, 2025, the Swedish Medical Products Agency (Läkemedelsverket) introduced a fast-track process for...

Upcoming webinar: what IVDR Article 5(5) means for your lab

Whether your lab is already working under IVDR and Article 5(5), evaluating tests, or preparing for transition, this...

IVDR reality check: are we moving fast enough?

As of February 2025, approximately 1,500 IVDR certificates have been issued. That’s progress — but is it enough? With...